Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rocuronium bromide and organ function

D R Bevan1

  • 1University of British Columbia, Faculty of Medicine, Department of Anaesthesia, Vancouver, Canada.

European Journal of Anaesthesiology. Supplement
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose-related effects of succinylcholine on the adductor pollicis and masséter muscles in children.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Jaw muscle tension after succinychloline in children undergoing strabismus surgery.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Dr R. A. Gordon 1911-1998.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Neuromuscular blockade. Inadvertent extubation of the partially paralyzed patient.

Anesthesiology clinics of North America·2002
Same author

Anaesthesia research is important.

European journal of anaesthesiology. Supplement·2002
Same author

Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient.

Anesthesiology·2001
Same journal

EuroNeuro 2010. Abstracts of the 6th EuroNeuro Congress. Porto, Portugal. February 4-6, 2010.

European journal of anaesthesiology. Supplement·2010
Same journal

Euroanaesthesia 2003. Abstracts of the joint meeting of the European Society of Anaesthesiologists and European Academy of Anaesthesiology, Confederation of European National Societies of Anaesthesiology, and Association of Anaesthetists of Great Britain & Ireland. May 31-June 3, 2003. Glasgow, Scotland.

European journal of anaesthesiology. Supplement·2008
Same journal

Evoked potentials in the ICU.

European journal of anaesthesiology. Supplement·2008
Same journal

Intracranial pressure monitoring.

European journal of anaesthesiology. Supplement·2008
Same journal

Phrenic nerve stimulation.

European journal of anaesthesiology. Supplement·2008
Same journal

Direct stimulation: a useful technique.

European journal of anaesthesiology. Supplement·2008
See all related articles

Rocuronium is primarily cleared by the liver. Hepatic disease may modestly prolong rocuronium

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Pharmacokinetics

Background:

  • Neuromuscular blocking drugs (NMBDs) exhibit diverse elimination pathways, including renal, hepatic, and other metabolic routes.
  • Understanding the primary route of excretion for NMBDs is crucial for predicting drug behavior in patients with organ dysfunction.
  • Rocuronium is an NMBD commonly used in anesthesia.

Purpose of the Study:

  • To investigate the impact of hepatic versus renal disease on the pharmacokinetics and pharmacodynamics of rocuronium.
  • To determine if hepatic disease significantly alters rocuronium's duration of action compared to renal disease.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic studies involving rocuronium in human subjects.
  • Analysis of rocuronium's elimination pathways, focusing on hepatic and renal excretion.

Related Experiment Videos

  • Comparison of rocuronium's duration of action in patients with hepatic disease versus those with renal disease.

    • Main Results:

    • Rocuronium is predominantly eliminated by the liver, with some renal excretion.
    • Pharmacokinetic and pharmacodynamic data suggest a greater prolongation of rocuronium's action in patients with hepatic disease compared to renal disease.
    • The observed effect of hepatic disease on rocuronium duration is likely modest.

    Conclusions:

    • Rocuronium's primary hepatic excretion suggests potential for prolonged action in liver dysfunction.
    • While hepatic disease may increase rocuronium's duration, the effect is modest.
    • The findings do not represent a contraindication for rocuronium use in patients with hepatic disease, though caution may be warranted.